Equipoise ”Balance of forces or interests”

Slides:



Advertisements
Similar presentations
Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.
Advertisements

The Importance of Beta-Blockers in Patients with Heart Failure: A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis.
Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure Presented at American College of Cardiology Scientific Sessions.
Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,
Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.
Heart Failure Ben Starnes MD FACC Interventional Cardiology
Treatment of Heart Failure: Beyond Medical Therapy
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
Presenter Disclosure Information John F. Beshai, MD RethinQ Trial Results Disclosures Information: The following relationships exist related to this presentation:
Clinical equipoise & the RCT dilemma
M. JESSUP Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.
Experimental studies Jean-François Boivin 25 October 2010.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.
SMMART-HF Surgery vs. Medical Treatment Alone for Patients with Significant MitrAl RegurgitaTion & Non-Ischemic Congestive Heart Failure Duke Heart Failure.
The Studies of Oral Enoximone Therapy in Advanced Heart Failure ESSENTIALESSENTIAL Presented at The European Society of Cardiology Congress 2005 Presented.
Clinical Review AbioCor® Implantable Replacement Heart H Julie Swain M.D. Cardiovascular Surgeon Ileana Piña M.D. Heart Failure Cardiologist DRAFT.
Mechanical Circulatory Support in Special Populations Renzo Y. Loyaga-Rendon MD.,PhD.. Assistant Professor Advanced Heart Failure Section University of.
1 One Year Follow-Up Results from AUGMENT-HF: A Multicenter Randomized Controlled Clinical Trial of the Efficacy of Left Ventricular Augmentation with.
Natural History of Heart Failure
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients with Heart Failure with preserved Ejection Fraction Effect of Spironolactone.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk Assessment and Comparative Effectiveness of.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Results of the Destination Therapy Post-Food and.
Welcome Clinical Trials October 11, 2016 Vernon M. Chinchilli, PhD
Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotensinconvertingenzyme; ARB, angiotensin receptor blocker; CRT-D,
Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;
Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy?  Wayne C. Levy,
University of Pennsylvania
Αντιμετώπιση καρδιακής ανεπάρκειας προχωρημένου και τελικού σταδίου
Forecasting the Impact of Heart Failure in the United States
Daniel J. Lenihan et al. BTS 2016;1:
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Cardiovacular Research Technologies
Figure 5 Schematic illustration of different clinical trial designs
Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection  Derek V. Exner, MD, MPH, David.
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
Outcome-adaptive randomization: some ethical issues
مسئولیتهای پزشکی درانجام اقدامات تشخیصی و درمانی (رابطه حقوقی پزشک و بیمار)
دکتر سعید غلامزاده مدیرکل پزشکی قانونی استان فارس
Ragavendra R. Baliga, MD, MBA  Heart Failure Clinics 
Obsessive Compulsive Disorder: A Clinical Update
INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.
Study Design Patients with LBBB and LV dysfunction
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Shadi Al Halabi et al. JACEP 2015;1:
Volume 9, Issue 8, Pages S3-S13 (August 2012)
Observational Studies vs. Randomized Controlled Trials (RCT)
BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.
Mirnela Byku, and Douglas L. Mann BTS 2016;1:95-106
Financial Disclosures
Juan A. Crestanello, MD, Richard C. Daly, MD 
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.
Anaerobic threshold responder analysis
Mahesh Anantha Narayanan et al. JACEP 2017;3:
Background. Current Perspectives on the Management of Iron Deficiency in Chronic Heart Failure.
Maria R. Costanzo et al. JCHF 2016;4:
The EXercise versus Angioplasty in Claudication Trial (EXACT): Reasons for recruitment failure and the implications for research into and treatment of.
Mahesh Anantha Narayanan et al. JACEP 2017;j.jacep
Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.
Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,
(A) Absolute and (B) change from baseline in 6 min walk distance over time for all patients and by Down syndrome status. (A) Absolute and (B) change from.
Illustration of a trial design to help evaluate the clinical accuracy of a test of ischaemia. Illustration of a trial design to help evaluate the clinical.
William T. Abraham et al. JCHF 2018;j.jchf
Today’s Agenda 9:45-10:00 Introduction
Summary of STICH trial patients included in the analysis of 6 min walk distance. Reasons for non-inclusion at each follow-up time are given. CABG, coronary.
Alignment of Comparative Effectiveness through MedaMACS
Number of patients treated at clinics that followed up fewer than 10 patients (2013–2016) or 20 patients (2012) and proportion of patients followed up.
Change in 6 min walk distance at 12 months in subgroups defined by baseline characteristics. The mean (95% CI) for the difference between CABG and medical.
Activity limitation scores across the 71 patients with PAVMs in the study cohort. Activity limitation scores across the 71 patients with PAVMs in the study.
Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.
Presentation transcript:

Equipoise ”Balance of forces or interests”

Clinical equipoise or the principle of equipoise provides the ethical basis for medical research that involves assigning patients to different treatment arms of a clinical trial. The term was first used by Benjamin Freedman in 1987. Freedman et al NEJM 1987

How is equipoise defined or interpreted How is equipoise defined or interpreted? Experiences of the individual physician or defined by the level of uncertainty that exists in the medical community Freedman et al NEJM 1987

REVIVE-IT RCT OMM versus LVAD Ambulatory, non-inotrope dependent cohort with advanced heart failure Receiving maximal medical therapy NYHA class III limitations LVEF < 35% 6 MWT distance < 300m Peak VO2 between 30 - 50% of predicted with an absolute value < 16 ml/Kg/min for men and < 14 ml/Kg/min for women

Speakers Ileana Pina, MD MPH Andrew Boyle, MD Larry Allen, MD